Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score.
Heba F TahaDalia Hamouda ElsayedReham SalemDoaa MandourMohammed BayomyHayam RashedMostafa KamelMohamed EldereyOla M ElfarargyPublished in: Contemporary oncology (Poznan, Poland) (2022)
Our results confirmed the benefits of treatment with docetaxel plus ADT in high-burden mHSPC with accepted tolerance. HALP score was found to be an independent predictive factor for benefit from therapy; we can apply it as an easy way to stratify patients for appropriate selection of treatment for better tolerance and outcome.
Keyphrases
- prostate cancer
- squamous cell carcinoma
- small cell lung cancer
- end stage renal disease
- chronic kidney disease
- stem cells
- newly diagnosed
- radiation therapy
- radical prostatectomy
- bone marrow
- prognostic factors
- combination therapy
- peritoneal dialysis
- peripheral blood
- rectal cancer
- patient reported outcomes
- smoking cessation